IR-MED, Inc.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company?s AI process to provide healthcare professionals with decision support in assessment of various disease conditions.

Recent News

IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment

Pina, Israel--(Newsfile Corp. - November 3, 2025) - IR-MED Ltd. (OTCQB: IRME) (the "Company" or "IR-Med"), a pioneer in artificial intelligence ("AI")-driven, non-invasive infrared spectrographic medical device developer, today announced that it has initiated the first-in-human clinical trial of its DiaSafe™ device – built on the proven "sensing the invisible" platform – specifically targeting DFUs. This milestone marks a critical step toward transforming...

2025-11-03 4:30 PM EST

IR-MED's Key Clinical and Media Milestones

Rosh Pina, Israel--(Newsfile Corp. - October 27, 2025) - IR-Med Inc. (OTCQB: IRME), (the "Company" or "IR-Med"), a medical technology company developing a non-invasive, AI-powered infrared spectroscopy platform for the assessment of pressure injuries and diabetic ulcers, today announced a series of recent milestones that highlight the Company's expanding visibility within the healthcare, investment, and media communities.Podium Presentation at Magnet & Pathway 2025 Conference - October 7,...

2025-10-27 4:05 PM EDT

IR-MED Investor Update Letter - Sept-2025

Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, today published an investor update. Dear Valued Investors,As we enter September 2025, in addition to Q2 financial reports and to the 8K recently published, I find it appropriate to update you on the developments within our Company. As you will see...

2025-09-16 4:05 PM EDT

IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones

ANE Research SymposiumRosh Pina, Israel--(Newsfile Corp. - June 23, 2025) - As the U.S. commemorated Juneteenth, last week, IR-MED Inc

2025-06-23 8:30 AM EDT

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment

IR-MED's noninvasive "Sensing the Invisible" technology platformRosh Pina, Israel--(Newsf

2025-05-05 8:30 AM EDT

Ready to Announce with Confidence?

Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us